Several therapeutic approaches targeting T cell activation (i.e., Janus kinase inhibitors) and proinflammatory cytokines (i.e., antibodies against IL17, IFNγ, and TNFα) have been developed for the treatment of autoimmune disorders. Here, IFNG is linked to autoimmune disease.